Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Sees Large Drop in Short Interest

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 295 shares, a decrease of 61.7% from the April 30th total of 770 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 64,427 shares, the short-interest ratio is currently 0.0 days.

Fidelity Disruptive Medicine ETF Stock Performance

NASDAQ FMED traded down $0.09 during trading hours on Friday, reaching $25.17. The stock had a trading volume of 6,024 shares, compared to its average volume of 13,556. The stock has a fifty day moving average of $24.84 and a 200 day moving average of $26.17. The stock has a market cap of $57.89 million, a P/E ratio of 41.33 and a beta of 0.84. Fidelity Disruptive Medicine ETF has a 52-week low of $22.80 and a 52-week high of $29.07.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A number of large investors have recently bought and sold shares of FMED. Jane Street Group LLC boosted its position in Fidelity Disruptive Medicine ETF by 0.8% in the first quarter. Jane Street Group LLC now owns 66,382 shares of the company’s stock valued at $1,567,000 after buying an additional 499 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Fidelity Disruptive Medicine ETF by 4.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 714,991 shares of the company’s stock valued at $19,712,000 after buying an additional 31,629 shares during the last quarter. BXM Wealth LLC purchased a new stake in Fidelity Disruptive Medicine ETF in the fourth quarter valued at approximately $243,000. Glass Jacobson Investment Advisors llc boosted its position in Fidelity Disruptive Medicine ETF by 44.0% in the 4th quarter. Glass Jacobson Investment Advisors llc now owns 1,260 shares of the company’s stock worth $34,000 after purchasing an additional 385 shares in the last quarter. Finally, Vise Technologies Inc. purchased a new stake in Fidelity Disruptive Medicine ETF in the 4th quarter worth approximately $234,000.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.